STUDY OF FACTORS AFFECTING ON THE DEVELOPMENT OF THE PHARMACEUTICAL SECTOR ENTERPRISES

© K. Golubtsova, R. Sahaidak-Nikitiuk, N. Demchenko

1. Introduction

Today, the pharmaceutical industry occupies an important place in the economy of Ukraine. A positive trend is the gradual growth of the domestic producer's share in the domestic market.

The share of medicines (drugs) manufactured at pharmaceutical companies in Ukraine is approaching 45%. The formation of the domestic pharmaceutical market necessitates conducting research on the current state and trends of pharmaceutical companies' development.

2. Analysis of recent research and publications

Problems of management of the enterprises of the pharmaceutical sector of Ukraine were considered in the work of many scientists: management standards [1, 2], the competitiveness of producers [3, 4], assortment policy [5, 6], social orientation of the industry [7], quality risk management [8], state and regional management [9], the influence of macro-focus on the activities of pharmaceutical organizations [10], logistics management [11], public administration [12], innovation policy [13, 14] etc.

3. Selection of previously unsettled parts of the general problem

But despite a lot of attention from academics, there are a number of questions regarding the management of pharmaceutical companies that require a thorough analysis of the current state of enterprises and the prospects for their development.

4. Formulation of goals (objectives) of the article

The article is to study the current state and trends of the pharmaceutical sector enterprises.

5. Materials and methods of research

The research used methods of analysis and synthesis, mathematical statistics and economic and mathematical methods.

6. Results and discussion

In the conditions of the crisis of 2014–2015, the growth rate of the consumer price index for pharmaceutical products substantially outweighed the growth rates of the pharmaceutical product sold; in recent years, this situation has been slowly but corrected (Fig. 1).
Such tendencies are explained by the restoration of macroeconomic indicators. After all, after 2015 (the decline in the gross domestic product (GDP) was 12 %), it was observed its gradual increase by 2–3 % annually.

The analysis volumes of sales of pharmaceutical products in Ukraine shows that in 2017, for the first time since 2013, an increase of 11 % in the volume of pharmaceutical products in US dollars was observed [16].

Correlation analysis of the growth rate of the volume of sales of pharmaceutical products (as a percentage of the previous year) with the tendencies of changes in consumer price indices on it testifies to a moderate relationship between these values (the calculated by the authors value of the coefficient of pair correlation is equal to $R = 0.63$).

The maintenance of the inflation rate provides the basis for forecasting a proportional increase in the volume of manufactured pharmaceutical products both in monetary terms and in natural equivalents.

The approximation of the volumes of pharmaceutical products produced by the polynomial trend line $(n = 3)$ with the forecast for 2021 (Fig. 2) implies a reduction in the rate of growth due to inflation, a slow recovery of the country's macroeconomic indicators, a decrease in the incomes of the population, and a change in the structure of household expenditures, the political and economic situation in the country, increased competition from foreign producers and other factors and the output to pre-crisis levels.

In 2017, both retail and hospital sales volumes of drugs were increased, but the pace of their growth was not even. Thus, retail sales increased by 20 % in cash equivalent and 7 % in real terms, hospitalized by 10 % and 15 % respectively.

The negative factors of the pharmaceutical industry’s development in Ukraine include the reduction of purchasing power of citizens. The analysis of the structure of total household expenditures shows an increase in the share of food expenditure and payment for housing and communal services to 80–85 %. Analysis of the Ukrainian market in terms of price segments demonstrates the significant advantage of low price segment (about 59 %) above the average (26 %) and high (15 %) that is inherent in countries with weak economies.
Comparison of the share of foreign and domestic producers in the domestic pharmaceutical market shows that the Ukrainian drugs are more accessible to the user because in foreign currency the share of foreign and domestic producers in terms of sales amounts to 63 % and 37 %, while in kind – 27 % and 73 %, respectively.

The low level of drug consumption in Ukraine gives experts the opportunity to argue that there is potential for the development of the pharmaceutical sector. The most influential factor is the expiration of patents on known drugs, which leads to an increase in the production of generics - authorized copies of original drugs, both in the world and in Ukraine. The price of generics is significantly cheaper than the original drugs, which gives their manufacturers an advantage in the market. So, Ukrainian drugs are cheaper than imported analogues by 4–16 times.

In Ukraine, innovative drugs are not enough. In money terms, their share is 9 %, that is, 91 % of all drugs sold in Ukraine, generics, and, unfortunately, most of their foreign production.

Scientific research in the pharmaceutical sector is not enough, as evidenced by the availability of their own patents for production, but their number is not sufficient in comparison with developed countries of the world. Among the leaders are PrAT FF "Darnitsa" (60 patents, 25 of them active), PAT "Farmak" (62 and 20, respectively), PJSC "Borschagovsky KFZ" (29 and 19), PJSC "Lekhim" (8 and 5), LLC FZ "Biopharma" (4 and 2).

The transition to the production of generics for most domestic enterprises is also an overwhelming problem, because the verification of the generic bioequivalence to the original drug costs from 2 to 4 million UAH. Therefore, for the development of the pharmaceutical sector of the health sector, there is definitely a need for investment. The negative trend towards a decrease in the capital investment index in the production of basic pharmaceuticals and pharmaceuticals, observed since the onset of the economic crisis, began to be rectified only in 2017 (Fig. 3) and the level of capital investment outweighed the previous figures by 12 %.

The problem of the pharmaceutical market of Ukraine is the fact that only 10–11 % of it belongs to the public procurement segment, therefore almost 90 % is sold in retail through a pharmacy network. Statistical data on the sales volume of pharmaceuticals through pharmacies, demographic indicators and calculated performance indicators of the pharmacy market of the nearest European neighbors of Ukraine (Table 1).

| Country         | Market volume, billion euro | Population, million people | Turnover per person | The number of pharmacies | Number of people served by 1 pharmacy | Pharmacy turnover per year |
|-----------------|-----------------------------|-----------------------------|---------------------|--------------------------|--------------------------------------|---------------------------|
| Poland          | 7.8                         | 38.5                        | 202.6               | 14716                    | 2616                                 | 530035.3                  |
| Romania         | 2.6                         | 19.9                        | 130.7               | 9429                     | 2111                                 | 275745.0                  |
| Ukraine         | 2                           | 42.3                        | 47.3                | 22474                    | 1882                                 | 88991.7                   |
| Hungary         | 1.9                         | 9.8                         | 193.9               | 3220                     | 3043                                 | 590062.1                  |
| Czech Republic  | 1.7                         | 10.6                        | 160.4               | 2804                     | 3780                                 | 606276.7                  |
| Bulgaria        | 1.5                         | 7.1                         | 211.3               | 4207                     | 1688                                 | 356548.6                  |
| Belarus         | 0.7                         | 9.5                         | 73.7                | 3196                     | 2972                                 | 219023.8                  |

The analysis of the results shows that in Ukraine the lowest indicators of population spending on the purchase of medicines (less than 50 euros per year); while in Poland, Hungary, Bulgaria this figure is 4 times higher. By the number of pharmacies – in Ukraine, the highest figures in absolute terms, therefore, the population...
served by one pharmacy – from the worst (Ukraine outstripped only Bulgaria: 1882 against 1688). This affects the effectiveness of each drug (88991.7 €/year vs. 606276.7 €/year in the Czech Republic 590,062.1 €/year in Hungary or 530035.3 €/year in Poland, that is 6–7 times less). If we take a sample of Poland – similar to Ukraine by population, it notes that in Ukraine 1.5 times the pharmacies that are definitely covered on their performance.

Kharkiv pharmaceutical complex consists of 11 enterprises, among which the main producers are LLC Pharmaceutical Company Zdorovya, OJSC Lekhim-Kharkov, AO Stoma, HGFP Zdorovye Naroda, OJSC HFZ Krasnaya Zvezda, Experimental Plant GNTsLS, "State Enterprise Chemical Reagents Plant", ZAO "Biolek". Two of them are included in the TOP 10 pharmacological enterprises of Ukraine in terms of pharmacy sales of LLC "FC Zdorovya" confidently ranked 5-th in the rating in recent years, and Lekhim-Kharkov OJSC improved its position by 2 points and took 7-th place. LLC "FC Zdorovya" occupies the leading positions on state purchases in Ukraine, and has occupied 2nd place in 2017, has improved its rating by 3 positions in comparison with the previous year, conceding only to the Irish company AbbVie. The share of the "Zdorovya" group of companies reaches 5.4 % of the total market segment of public procurement of pharmaceuticals.

For research and comparative analysis, 4 pharmaceutical enterprises of the Kharkiv region were selected: Pharmaceutical Company Zdorovya LLC, PJSC "Lekhim-Kharkiv", JSC "Stoma", PJSC "KhFZ" Chervona Zirka. The results of calculating the share of each type of stocks of pharmaceutical enterprises in the Kharkiv region [17, 18] are summarized in Table 2.

| Structure of stocks in the balance of pharmaceutical enterprises of the Kharkiv region | 2014   | 2015   | 2016   | 2017   |
|---------------------------------------------|--------|--------|--------|--------|
| LLC "Pharmaceutical company "Zdorovya"     |        |        |        |        |
| inventories                                | 49.94  | 44.44  | 48.39  | 48.04  |
| unfinished production                       | 14.44  | 11.62  | 12.57  | 12.38  |
| finished goods                              | 33.12  | 41.03  | 34.66  | 36.94  |
| products                                    | 2.49   | 2.92   | 4.37   | 2.65   |
| PJSC "Lekhim-Kharkiv"                      |        |        |        |        |
| inventories                                | 67.29  | 66.36  | 67.49  | 72.31  |
| unfinished production                       | 8.39   | 8.23   | 7.50   | 12.58  |
| finished goods                              | 24.31  | 25.41  | 25.01  | 15.10  |
| products                                    | 0.00   | 0.00   | 0.00   | 0.00   |
| JSC "Stoma"                                |        |        |        |        |
| inventories                                | 51.78  | 51.13  | 57.84  | 66.11  |
| unfinished production                       | 7.79   | 5.03   | 8.25   | 8.00   |
| finished goods                              | 40.44  | 43.83  | 33.91  | 25.89  |
| products                                    | 0.00   | 0.00   | 0.00   | 0.00   |
| "KhFZ" Chervona Zirka                      |        |        |        |        |
| inventories                                | 55.27  | 57.71  | 63.08  | 53.02  |
| unfinished production                       | 6.90   | 3.71   | 5.60   | 3.66   |
| finished goods                              | 37.66  | 38.56  | 31.32  | 43.32  |
| products                                    | 3.71   | 0.02   | 0.00   | 0.00   |

The share of production stocks of the Pharmaceutical Company Zdorovya LLC is almost unchanged and accounts for half of all stocks, and a third falls on finished products. The share of unfinished production and goods varies from 12.5 to 14.5 % and from 2.5 to 4.5 %, respectively. In PJSC "Lekhim-Kharkiv", 2/3 of the stock falls on production, and their share is increasing, 1/4 – on finished products, and its share decreases. The share of work in progress ranges from 7.5 % to 12.5 %. There is almost no stock in the goods. For JSC "Stoma" we note an increase in the share of production stocks from 52 % to 66 %, and the reduction of finished products from 40 % to 26 %. The share of work in progress ranges from 5 % to 8 %, inventories are almost non-existent. According to the share of production and finished products, the stock structure of PJSC "KhFZ" Chervona Zirka "is similar to the corresponding structure of Pharmaceutical company "Zdorovya" LLC. The share of incomplete production varies within the limits of 4 7 %, the stock in the goods is insignificant.

A correlation analysis was chosen for the study [19, 20]. It allows to set the level of dependence of one random variable on the other. The value of the relationship between random variables by the magnitude of the correlation coefficient is set according to the rule: 0≤Rxy≤0.2 is very weak; 0.2≤Rxy≤0.3 is weak; 0.3≤Rxy≤0.5 moderate; 0.5≤Rxy≤0.7 average; 0.7≤Rxy≤0.8 strong; 0.8≤Rxy≤1.0 is very strong.

Calculated values of the coefficient of pair correlation between the values of net profit and stocks of enterprises in the Kharkiv region are presented in Table 3.
Almost all selected pharmaceutical companies have a strong and very strong link between stock availability and profitability.

7. Conclusions
1. The trends, typical for the modern pharmaceutical market, which testify to the gradual growth of volumes of manufactured products and the correction of the situation caused by the crisis that has developed in the country, are analyzed.
2. The conducted studies revealed an increase of 11% in the volume of pharmaceutical products in US dollars, while the approximation of volumes of manufactured pharmaceutical products in Ukraine has a polynomial trend line and implies a reduction in the rates of its growth due to inflation and their output to pre-crisis levels. The negative trend is also the index of capital investments in the production of basic pharmaceuticals and pharmaceuticals of Ukraine in 2011–2017.
3. Analysis of the stocks of pharmaceutical enterprises in the Kharkiv region shows that almost all companies account for a third of the stock of finished products, the share of work in progress ranges from 12.5%.
4. On the basis of correlation analysis, for almost all selected pharmaceutical companies, a strong connection was found between stock availability and profitability of the enterprise.
5. The study of the current state and trends in pharmaceutical companies' development has made it possible to conclude that the profitability of enterprises in the pharmaceutical sector depends on the level of organization of logistics management (inventory management), which will allow them to get rid of excess costs and reach a new level of production of high-quality pharmaceutical products.

The prospect of further research should be the scientific substantiation of the use of marketing logistics tools in the context of increasing the competitiveness of domestic pharmaceutical products and pharmaceutical industry.

### Value of the pair correlation coefficients between the values of net profit and the stocks of the Kharkiv region’s pharmaceutical enterprises

| Enterprise | $R_{xy}$ | Interpreting the result |
|------------|----------|-------------------------|
| LLC "Pharmaceutical company Zdorovya" | 0.75 | Strong, straight |
| PJSC "Lekhim-Kharkiv" | 0.90 | Very strong, straight |
| JSC "Stoma" | -0.96 | Very strong, inverse |
| "KhFZ" Chervona Zirka" | 0.98 | Very strong, straight |

### References
1. Hromovych B. P. Standarty farmatsevtychnoho upravlinnia // Farmatsevtychnyi zhurnal. 2004. Issue 3. P. 18–28.
2. Hromovych B. P., Tereshchuk S. I., Chukhrai I. L. Orhanizatsia ta ekonomika farmatsii / ed. by Hromovych B. P., Tereshchuk S. I. Vinnytsia: NOVA KNYA, 2009, 816 p.
3. Gholamhossein M., Hosein S. The Importance of Competitiveness in New Internationalized and Competitive Environment of Pharmaceutical Industry // Iranian journal of pharmaceutical research. 2014. Issue 13 (2). P. 351–352.
4. Frolova H. I., Frolova V. Yu. Konkurentospromozhnist pidpryjemstv farmatsevtychnoi haluzi Ukrainy // Visnik Berdianskoho universytetu navedenemuhu i biznesu. 2012. Issue 1 (17). P. 146–152.
5. Kotvit ska A. A., Kostiuk V. H. Doslidzhennia suchasnykh pidkho dov do formuvannia asortymentnoi polityky vitnychnianykh farmatsevtychnykh pidpryjemstv // Sotsialna farmatsiia v okhoroni zdorovia. 2016. Vol. 2, Issue 2. P. 37–43.
6. Kotvit ska A. A. Metodolohiia sotsialnoi spravedlyvosti farmatsevtychnoho zabezpechennia naselennia // Farmatsevtychnyi zhurnal. 2008. Issue 2. P. 8–12.
7. Kutsenko V. Zdorovia natsiyi yak stratehichniy resurs derzhavy // Visnyk Natsionalnoi Akademii Nauk Ukrainy. 2009. Issue 6. P. 44–51.
8. Lebedynets V. O., Kovalenko S. M. Otsiniuvannia, analizuvannia ta upravlinnia ryzykami dlia yakosti na farmatsevtychnomu pidpryjemstvi // Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii. 2011. Issue 6 (20). P. 10–15.
9. Nemchenko A. S., Khomenco V. M., Yarmola I. K. Ekspertna otsinka problem derzhavnoho ta rehionalnoho upravlinnia farmatsevtychnoi haluzi // Farmatsevtychnyi zhurnal. 2008. Issue 1. P. 3–9.
10. Pestun I. V., Mnasiko Z. M. Stan ta perspektyvy makrotrendu na diaistvanii farmatsevtychnykh orhanizatsii v Ukraini // Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii. 2008. Vol. 1. Issue 1. P. 8–14.
11. Lohistychniy menedzhment farmatsevtychnoho pidpryjemstva: monograph / Posylkina O. V., Sahaidak R. V., Zaporozhye O. V., Yurchenko O. M. Ekonomichnykh systemakh: monograph. Kyiv: Vyd.Dim «Inzhel», SP” Liburkina L. M., 2004. 304 p.
12. Butnyk O. M. Ekonomiko-matematychne modeliuvannia perekhidyntnykh protsesiv u sotsialno-ekonomicnykh systemakh: monograph. Kharkiv: Vyd.Dim «Inzhel», SP” Liburkina L. M., 2004. 342 p.
